Answers are grounded in this paper and cite their sources.
To the Editor: In the final, 10-year outcomes of the CheckMate 067 trial reported by Wolchok et al. (Jan. 2 issue), 1 the combination of nivolumab and ipilimumab resulted in an unprecedented increase in overall and melanoma-specific survival, as compared with ipilimumab alone. We should be wary of the fact that this combination was not designed to be compared with nivolumab alone, and the difference in survival between the two trial groups was not significant. This finding is noteworthy, given that nivolumab alone had an incidence of adverse events of only 25% (as compared with 63% in the combination group). Among . . .
No takes yet. Share an insight, caveat, or question.
Hodi et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: